Contracts & Pricing November 4, 2024 Why I Chose IntegriChain: A Journey from Tech Giants to Transforming... 2 Minute Read Read the latest on the CMS September Final Rule Overview & a Controversial 340B Rebate Policy
Contracts & Pricing October 31, 2024 Industry Shifts: A Closer Look at Recent CMS and J&J Announcements 3 Minute Read Read the latest on the CMS September Final Rule Overview & a Controversial 340B Rebate Policy
Contracts & Pricing September 4, 2024 Understanding the $35 Patient Out-of-Pocket Strategy: Implications for Pharmaceutical Manufacturers 2 Minute Read Katie Herrick and Dan Landis, consultants from Blue Fin Group, discuss how pharmaceutical companies are adapting to the changing healthcare environment by focusing on improving patient access and affordability.
Contracts & Pricing September 4, 2024 Key Developments in Pharmaceutical Pricing Regulations 4 Minute Read Nick Lynch, Partner of Federal Compliance Solutions (FCS) discusses insights into recent developments in pharmaceutical pricing, focusing on government programs like 340B, Medicaid Drug Rebate Program (MDRP), Medicare Part...
Market Access Blogs August 28, 2024 Industry Updates, Biosimilar Barriers, and & the Impact of IRA Medicare... 6 Minute Read Read the latest on Industry Updates, Biosimilar Barriers, and the Impact of Drug Price Negotiations.
Market Access Blogs July 29, 2024 The 340B Saga, New Orphan Drug Exclusion Criteria & Drug Shortages... 4 Minute Read Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
Market Access Blogs June 28, 2024 States Influence Drug Pricing and Access, Specialty Pharmacies Evolve to Accommodate... 4 Minute Read Read the latest on how states influence drug pricing and access, specialty pharmacies evolution to supoprt cell & gene therapies, and Walgreens entering the CGT arena.
Contracts & Pricing June 12, 2024 The Wild Ride of Medicare Part D Payer Challenges on Expenditures... 3 Minute Read Learn about the IRA's changes to Part D benefits have created uncertainty for both manufacturers and payers.
Market Access Blogs May 30, 2024 IRA Part D Redesign, New Gene Therapies Give Hope for Patients,... 5 Minute Read Discover the latest on IRA Part D Redesign Financial Implications, New Gene Therapies Give Newfound Hope for Patients, and Impact of Credit Card Fees in Government Pricing.
Contracts & Pricing April 24, 2024 Changing Pharmacy Reimbursements with CVS, FSS/IFF Reporting Alert & the Latest... 3 Minute Read Discover the latest on the Pharmacy Reimbursements for CVS, FSS/IFF Reporting Alert, and the 340B Drug Discount Program.
